2009•Critical CareOpen access

Micafungin for the treatment of pediatric invasive fungal infections

Antonio Carlos Arrieta, NL Seibel, T. J. Walsh, L Arnold, Groll Ah

Abstract

Pediatric patients in the ICU are highly vulnerable to invasive fungal infections [ 1 ]; Candida has been reported to be the third most common pathogen in pediatric ICU wards [ 2 ]. However, information on new antifungal therapies in children remains limited. Micafungin (MICA) is a once-daily antifungal agent of the echinocandin class.

Open-access reader

About this research paper

What this paper is about

Why it matters

A significance statement is not available in the OpenAlex record.

Key contribution

A contribution statement is not available in the OpenAlex record.

Method / approach

Method details are not available in the OpenAlex metadata.

Main findings

Findings are not separately available in the OpenAlex metadata.

Limitations

Limitations are not available in the OpenAlex metadata.

Applications

Application details are not available in the OpenAlex metadata.

Available abstract

Key concepts: Micafungin, Echinocandin, Medicine, Antifungal, Intensive care medicine, Echinocandins, Antifungal drugs, Invasive candidiasis